Sanofi SA generated sales of €10.1 billion in the second quarter with Dupixent, jointly developed with Regeneron Pharmaceuticals Inc, making the single biggest contribution to turnover. Sales for the company as a whole increased by 15.7%, while sales for Dupixent, an anti-inflammatory drug, rose by 58% to €1.96 billion.
